Terms of Use for ca/b2/srpe0546_NBK539419.tar.gz; Pharmacoeconomic Review Report: Cladribine (Mavenclad) (EMD Serono): Indication: As monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability. Cladribine is generally recommended in RRMS patients who have had an inadequate response to, or are unable to tolerate, one or more therapies for RRMS; Canadian Agency for Drugs and Technologies in Health; 2018; NBK539419

For each document, read the license and copyright statements in the XML or PDF files before reusing or redistributing any part of the document. The license and copyright statements define what uses of the document are permitted, and apply to all associated files, including images and supplementary material. The terms and conditions of use are not identical for all documents.

If there is no license or copyright statement in the XML or PDF files, then the document is in the public domain. No permission is needed to reproduce or distribute public domain content, but the authoring institute or agency must be given appropriate attribution.

Contact the publisher if you have any questions about the permissible uses of the documents.  For more information, see the Bookshelf Copyright Notice  (http://www.ncbi.nlm.nih.gov/books/about/copyright/).